Breaking News

INC Research Names General Medicine EVP

July 3, 2013

Braithwaite brings 25 years of experience

Ian M. Braithwaite, Ph.D., has been appointed executive vice president and general manager of General Medicine at INC Research. Dr. Braithwaite will provide global leadership for the company’s General Medicine business unit, which specializes in conducting trials in areas ranging from infectious disease, respiratory disease, women’s health, immunology and inflammation, gastrointestinal disease and ophthalmology. Dr. Braithwaite will be based out of INC’s Camberley, UK, office.
Dr. Braithwaite brings 25 years of experience in the CRO and biopharmaceutical industries with particular expertise in immuno-inflammatory diseases. He joins the company from PPD, where he served as global therapeutic area head, General Medicine. Under his leadership, this unit experienced significant growth in revenue and backlog, boosted staff utilization and reduced turnover. Dr. Braithwaite previously served in other senior positions at PPD, including executive director and therapeutic head for Europe, Middle East and Africa, and executive director, project management performance.
“We are excited to add an experienced leader like Dr. Braithwaite to our therapeutic leadership team,” said Jamie Macdonald, INC’s chief executive officer. “Ian’s deep therapeutic experience both in the CRO and biopharmaceutical space provides a unique perspective on the efficient management of clinical development programs. As a CRO structured around a strong therapeutic focus, world-class leadership in our business units is critical to our success. Ian is responsible for significantly growing our presence in this important fast-growing market segment.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks